NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/14/2022
Back to search
Official data from USPTO
ABALOS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
06/14/2022
Trademark type
Word
Nice classes
5
Filing date
07/27/2020
Registration date
06/14/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/14/2022
Last transaction
06/14/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
16
Owner location
Duesseldorf, DE
Examiner
TANNER, MICHAEL R
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Abalos Therapeutics GmbH
Abalos Therapeutics GmbH
Representatives
Michael A Whittaker ACUITY LAW GROUP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalmedical and veterinary preparations for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing arenaviruses for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a lymphocytic choriomeningitis virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing an Ippy virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Lassa virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Mobala virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Mopeia virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing an Allpaahuayo virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing an Amapari virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Bear Canyon virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Chapare virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Cupixi virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Flexal virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Guanarito virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Junin virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Latino virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Machupo virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing an Oliveros virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Parana virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing an Pichinde virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing an Pirital virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Sabia virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Tacaribe virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Tamiami virus for use in treating cancer; pharmaceuticalmedical and veterinary preparations containing a Whitewara Arroyo virus for use in treating cancer; cancer drugspharmaceutical preparations for use in treating cancer; immuno-oncology drugspharmaceutical preparations for use in treating cancer; vaccines
Publications
History of USPTO decisions and trademark events.
26 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/14/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/28/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/28/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/28/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/29/2022
PUBO
PUBLISHED FOR OPPOSITION
03/29/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/09/2022
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/19/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/18/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/20/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/20/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/30/2021
GNFR
FINAL REFUSAL E-MAILED
07/30/2021
CNFR
FINAL REFUSAL WRITTEN
07/30/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/08/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/08/2021
ALIE
ASSIGNED TO LIE
07/07/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/18/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/19/2020
GNRT
NON-FINAL ACTION E-MAILED
11/19/2020
CNRT
NON-FINAL ACTION WRITTEN
11/19/2020
DOCK
ASSIGNED TO EXAMINER
11/12/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/25/2020
NWAP
NEW APPLICATION ENTERED
07/30/2020
Continuous trademark protection
Get notified about every new filing that threatens ABALOS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.